| 靶点: |
GP IIb-IIIa |
| 体内研究: |
SR121566A leads to dose-dependent increases in TTO, a statistically significant increase being observed at the doses of 0.3 mg/kg (473%) and 30 mg/kg (771%), respectively. |
| 参考文献: |
1. Herault JP, et al. Effect of SR121566A, a potent GP IIb-IIIa antagonist on platelet-mediated thrombin generation in vitro and in vivo. Thromb Haemost. 1998 Feb;79(2):383-8. 2. Lorrain J, et al. Effects of SanOrg123781A, a synthetic hexadecasaccharide, in a mouse model of electrically induced carotid artery injury: synergism with the antiplatelet agent clopidogrel. J Pharmacol Exp Ther. 2004 Apr;309(1):235-40. |
| 保存条件: |
RT |
| 配置溶液浓度参考: |
|
1mg |
5mg |
10mg |
| 1 mM |
2.317 ml |
11.587 ml |
23.174 ml |
| 5 mM |
0.463 ml |
2.317 ml |
4.635 ml |
| 10 mM |
0.232 ml |
1.159 ml |
2.317 ml |
| 50 mM |
0.046 ml |
0.232 ml |
0.463 ml |
|
| 注意: |
部分产品我司仅能提供部分信息,我司不保证所提供信息的权威性,仅供客户参考交流研究之用。 |